Veracyte, Inc. (NASDAQ:VCYT) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Posted by Stanley Muller on Jun 13th, 2026

Shares of Veracyte, Inc. (NASDAQ:VCYT – Get Free Report) have earned an average recommendation of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $47.5714.

A number of equities analysts recently commented on the stock. Guggenheim reduced their price objective on shares of Veracyte from $50.00 to $45.00 and set a “buy” rating for the company in a research note on Monday, March 30th. UBS Group boosted their price objective on shares of Veracyte from $48.00 to $52.00 and gave the stock a “buy” rating in a research note on Wednesday, May 6th. Canaccord Genuity Group boosted their price objective on shares of Veracyte from $40.00 to $42.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. Wolfe Research assumed coverage on shares of Veracyte in a research note on Tuesday, June 2nd. They issued an “outperform” rating and a $55.00 price objective for the company. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of Veracyte in a research note on Friday, March 27th.

Check Out Our Latest Analysis on Veracyte

Insider Buying and Selling

In other Veracyte news, CEO Marc Stapley sold 138,051 shares of Veracyte stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $50.12, for a total value of $6,919,116.12. Following the transaction, the chief executive officer directly owned 440,494 shares of the company’s stock, valued at approximately $22,077,559.28. The trade was a 23.86% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Robert S. Epstein sold 10,000 shares of Veracyte stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $44.01, for a total transaction of $440,100.00. Following the completion of the transaction, the director directly owned 52,446 shares in the company, valued at $2,308,148.46. This represents a 16.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 202,967 shares of company stock valued at $9,881,831 over the last ninety days. Company insiders own 1.40% of the company’s stock.

Hedge Funds Weigh In On Veracyte

Several institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Veracyte by 5.0% in the third quarter. Vanguard Group Inc. now owns 8,504,088 shares of the biotechnology company’s stock worth $291,945,000 after purchasing an additional 403,737 shares during the last quarter. Artisan Partners Limited Partnership grew its holdings in Veracyte by 16.6% in the third quarter. Artisan Partners Limited Partnership now owns 7,370,467 shares of the biotechnology company’s stock worth $253,028,000 after purchasing an additional 1,048,692 shares during the last quarter. ARK Investment Management LLC grew its holdings in Veracyte by 17.5% in the third quarter. ARK Investment Management LLC now owns 4,465,775 shares of the biotechnology company’s stock worth $153,310,000 after purchasing an additional 665,686 shares during the last quarter. State Street Corp grew its holdings in Veracyte by 3.8% in the fourth quarter. State Street Corp now owns 4,360,913 shares of the biotechnology company’s stock worth $183,594,000 after purchasing an additional 161,239 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its holdings in Veracyte by 3.2% in the third quarter. Dimensional Fund Advisors LP now owns 3,118,166 shares of the biotechnology company’s stock worth $107,042,000 after purchasing an additional 95,664 shares during the last quarter.

Veracyte Stock Down 0.2%

Shares of NASDAQ:VCYT opened at $47.33 on Monday. The company has a market capitalization of $3.78 billion, a price-to-earnings ratio of 43.42 and a beta of 1.98. Veracyte has a 52 week low of $22.61 and a 52 week high of $50.71. The firm has a 50 day moving average of $39.43 and a 200 day moving average of $39.33.

Veracyte (NASDAQ:VCYT – Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.34 by $0.18. The company had revenue of $139.07 million during the quarter, compared to the consensus estimate of $130.36 million. Veracyte had a net margin of 16.25% and a return on equity of 9.07%. Veracyte’s revenue for the quarter was up 21.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.31 earnings per share. On average, sell-side analysts expect that Veracyte will post 1.29 EPS for the current year.

Veracyte Company Profile

(Get Free Report)

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.